CSIMarket Company Name, Ticker, Competitors, else..
 
Biote Corp   (NASDAQ: BTMD)
 
Price: $1.5450 $0.00 -0.323%
Day's High: $1.600000023841858 Week Perf: -5.79 %
Day's Low: $ 1.51 30 Day Perf: -5.21 %
Volume (M): 77,400 52 Wk High: $ 3.54
Volume (M$): $ 0 52 Wk Avg: $2.27
Open: $1.55 52 Wk Low: $1.27



 Market Capitalization (Millions $) 44
 Shares Outstanding (Millions) 29
 Employees 223
 Revenues (TTM) (Millions $) 184
 Net Income (TTM) (Millions $) 7
 Cash Flow (TTM) (Millions $) 16
 Capital Exp. (TTM) (Millions $) 7

Business Description


Biote Corp is a pharmaceutical company that focuses on the development and commercialization of innovative therapies for various diseases. They have a diverse pipeline of potential treatments, ranging from small molecule drugs to gene therapies. The company has a strong emphasis on research and development, investing heavily in cutting-edge technologies to bring breakthrough treatments to the market. With a dedicated team of scientists and experts, Biote Corp aims to improve patient outcomes and address unmet medical needs worldwide.


   Company Address: 1875 W. Walnut Hill Ln Irving 75038 TX
   Company Phone Number: 604-1246   Stock Exchange / Ticker: NASDAQ BTMD


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   





Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) 15.45
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 0.24
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.37
Working Capital Ratio 1.43
Leverage Ratio (MRQ) -
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) 0.1 $
Revenues (TTM) 6.41 $
Cash Flow (TTM) 0.55 $
Cash 0.39 $
Book Value -
Dividend (TTM) 0.02 $

Efficiency Current
Revenue per Employee (TTM) 823,009
Net Income per Employee (TTM) 31,753
Receivable Turnover Ratio (TTM) 24.43
Inventory Turnover Ratio (TTM) 2.95
Asset Turnover Ratio (TTM) 1.79

Profitability Ratios Current
Gross Margin (MRQ) 64.89 %
Operating Margin (MRQ) -7.93 %
Net Margin (MRQ) -16.79 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) 30.98 %

Management Effectiveness Current
Return On Assets (TTM) 6.91 %
Return On Investment (TTM) 10.35 %
Return On Equity (TTM) -
Dividend Yield 0.97 %
Pay out Ratio (TTM) 20 %



Biote's Segments
Product Revenue    197.31 % of total Revenue
Unsatisfied Pellet Procedures    5.29 % of total Revenue
Pellet Procedures Product Revenue    139.27 % of total Revenue
Dietary Supplements    50.63 % of total Revenue
Service Revenue United States    2.22 % of total Revenue
Deferred Revenue Long-term    0.6 % of total Revenue
US    200.53 % of total Revenue
Member    201.59 % of total Revenue

  Biote Outlook

On March 12 2024 the Biote provided following guidance

Biote Corp announced their financial results for the fourth quarter and full year 2023, with a focus on preventive health care and personalized hormone optimization. The company reported revenue of $45.7 million for the fourth quarter, representing a 2.7% increase compared to the previous year. This revenue figure was in line with the company's pre-released financial guidance.

Throughout the year, Biote Corp has been a leader in providing solutions for preventive health care through personalized hormone optimization and therapeutic wellness. The company's focus on delivering personalized care has led to a steady increase in revenue, reflecting the growing demand for personalized health solutions.
<...





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.